SCHEMBL2513021

SCHEMBL2513021

NC(C(=O)Nc1ccc(F)cn1)C1CCCO1

nearest known ligand 0.46

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 10/20 0.46
▸ FFAR2 O15552 1/20 0.43
▸ POLB P06746 1/20 0.40
▸ TRPA1 O75762 1/20 0.39
▸ DEGS1 O15121 1/20 0.39
▸ MAPK1 P28482 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4103735 0.82 GRM5 (0.52) GRM5FFAR2POLB
SCHEMBL12201477 0.82 GRM5 (0.52) GRM5FFAR2POLB
SCHEMBL12201476 0.79 GRM5 (0.56) GRM5FFAR2POLBMAPK1
SCHEMBL2668326 0.77 GRM5 (0.54) GRM5FFAR2POLB
SCHEMBL4114224 0.75 GRM5 (0.50) GRM5FFAR2POLBMAPK1
SCHEMBL4102212 0.74 GRM5 (0.46) GRM5FFAR2DEGS1
SCHEMBL16751973 0.73 FFAR2 (0.47) GRM5FFAR2TRPA1
SCHEMBL4114293 0.70 GRM5 (0.46) GRM5POLB
SCHEMBL4109054 0.70 GRM5 (0.49) GRM5
SCHEMBL2520163 0.70 GRM5 (0.49) GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034822-B2 Glucokinase activators TAKEDA SAN DIEGO, INC. (US) 2011-10-11 — — US disclosed
EP-2001875-A2 GLUCOKINASE ACTIVATORS Takeda San Diego, Inc. (US) 2008-12-17 — — EP disclosed
WO-2007104034-A2 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. (US) 2007-09-13 — — WO disclosed
US-20070213349-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213349-A1 GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 GRM5 2182/4885FFAR2 2244/4885POLB 2173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback